The Fly

Harrow Health price target raised to $24 from $17 at Lake Street

Lake Street analyst Brooks O’Neil raised the firm’s price target on Harrow Health (HROW) to $24 from $17 and keeps a Buy rating on the shares after Harrow completed the acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products from Novartis (NVS) and affirmed 2023 guidance. Given the new rights along with fortisite and atropine, the "table is set for big things" from Harrow in 2023, Lake Street tells investors.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on HROW:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More